Dihydroartemisinin is a drug used to treat malaria. Dihydroartemisinin is the active metabolite of all artemisinin compounds (artemisinin, artesunate, artemether, etc.) and is also available as a drug in itself.
Artificial intelligence has exploded in popularity and is being harnessed by some scientists to predict which molecules could treat illnesses, or to quickly screen existing medicines for new applications.
The association between substandard or falsified (SF) antibiotics and antimicrobial resistance (AMR).
A Purdue researcher is taking a giant leap forward in the fight against drug-resistant strains of malaria in developing countries.
Researchers conducted a systematic review to describe the epidemiology of submicroscopic and microscopic malaria infections during pregnancy.
A large LSTM-led trial confirms new antimalarial, dihydroartemisinin-piperaquine, is more effective at preventing malaria than current WHO recommended treatment but does not improve adverse birth outcomes.
Researchers describe the genetic epidemiology and dynamics of the Plasmodium falciparum responsible for malaria outbreaks in Attapeu Province, Laos.
A new WWARN meta-analysis commissioned by the World Health Organization (WHO) which informed a change to its treatment guidelines has been published in The Lancet.
Researchers assessed the effectiveness of artemisinin-based antimalarials in the management of COVID-19.
Caused by SARS-CoV-2, the ongoing COVID-19 pandemic has led to over 121.2 million cases and over 2.6 million deaths worldwide. An interesting new study examines the potential antiviral activity of compounds present in the plant Artemisia annua L.
Researchers in the United States have shown that extracts of an aromatic herb called Artemisia annua inhibit the replication of severe acute respiratory coronavirus (SARS-CoV-2) – the agent responsible for the current coronavirus disease 2019 (COVID-19) pandemic.
Now, a new study published in the preprint server bioRxiv in July 2020 reports on the antiviral activity of two drugs found in an antimalarial drug currently in phase II trials in South Korea, called Pyramax.
A new study describing the outcome of a clinical trial of two malaria treatment protocols involving the use of triple therapies based on artemisinin reports their high efficacy and low adverse effects.
Researchers from the Liverpool School of Tropical Medicine have shown the large potential impact of a completely new type of antimalarial drug that kills mosquitoes, as opposed to existing drugs that target the parasite, to reduce the spread of malaria.
The spread of a single multidrug resistant malaria parasite strain in Vietnam is cause for alarm say researchers.
A novel strategy to screen pregnant women for malaria with rapid diagnostic tests and treat the test-positive women with effective antimalarials does not lower the risk of adverse pregnancy outcomes compared with treating all pregnant women with the malaria preventive sulfadoxine-pyrimethamine (SP) in sub-Saharan Africa, according to an open label randomized trial published this week in PLOS Medicine by Feiko ter Kuile, of the Liverpool School of Tropical Medicine, and colleagues.
Researchers at LSTM, working with colleagues at the Centres for Disease Control and Prevention USA, the Kenya Medical Research Institute, and from the London School of Hygiene and Tropical Medicine, have completed a study to assess the acceptability among pregnant women and health providers in Kenya of a new drug as an alternative to the standard drug used to prevent malaria in pregnancy.
Pregnant women can be protected from malaria, a major cause of prematurity, low birth weight and death in infants in Africa, with dihydroartemisinin-piperaquine , an artemisinin combination therapy that is already widely used to treat malaria in adults, according to a study by researchers at UC San Francisco and in Uganda.
Researchers at LSTM, working with colleagues of the Centres for Disease Control and Prevention (CDC) in Kenya and USA, and from the Kenya Medical Research Institution have found that a new drug may be more effective at preventing malaria in pregnant woman, especially where there is resistance to the current treatments.
Research success through collaborative efforts of chemists and engineers from Berlin/Potsdam and Magdeburg. All of the best currently available pharmaceuticals against malaria can now be produced in pure form using a single process, even from the waste of the plant-extraction.
'Dihydroartemisinin-piperaquine is more effective than artemether-lumefantrine, and has fewer side effects than artesunate-mefloquine' concludes a systematic review published by the Cochrane Infectious Disease Group, hosted by LSTM.